Medicinteknik och diagnostikI-Flow Corporation
I-Flow Corporation (NASDAQ:IFLO) manufactures and markets the ON-Q PainBuster® Post-Operative Pain Relief System. I-Flow has built a reputation in the medical and health care industry as an innovator in drug delivery technology. Through product innovation, I-Flow has emerged as a leader in the growing field of pain relief, offering cutting-edge therapies to physicians and their patients. I-Flow is located in Lake Forest, Calif., and is available on the Web at www.iflo.com.
ON-Q PainBuster reduces the need for patients to take narcotics (such as morphine) following surgery by delivering anesthetic directly to an incision site continuously over the course of five days. ON-Q PainBuster has been found to reduce narcotics intake by 40 to 70 percent depending upon the surgery and helps patients get out of the hospital and back to their normal lives faster. ON-Q was cleared by the FDA in May 1998, and since then I-Flow has been focused on building a wealth of clinical data to support the use of ON-Q for different types of surgeries and drive physician demand.Organ Recovery Systems
Founded in 1998, Organ Recovery Systems is a Chicago-area start-up developing technologies and services to improve the quality and quantity of organs, tissues and cells for transplantation. The company is organized into three operating groups: the Medical Devices Group, developing perfusion-based “life support” devices for the preservation, treatment and transport of organs for transplantation; a Perfusion Services Group that helps transplant centers and organ procurement organizations (OPOs) employ proprietary perfusion techniques for evaluation and therapy of donor kidneys prior to transplant; and the Charleston, S.C., Research Center that develops new technologies for cell and tissue cryopreservation and evaluation. More information about Organ Recovery Systems is available at www.organ-recovery.com. Proxima Therapeutics
Proxima Therapeutics develops and markets site-specific therapies that deliver brachytherapy, or internal radiation therapy, for breast and brain tumors. Its devices target radiation to the area where tumors are most likely to recur, minimizing exposure to healthy tissue. Proxima’s proprietary radiation delivery technology may have future applications for treating other solid tumors.
Proxima has developed the MammoSite Radiation Therapy System for breast cancer and the GliaSite Radiation Therapy System for brain cancer. Schwartz initial PR campaign focused on MammoSite, which delivers accelerated partial breast irradiation and facilitates the adoption of breast conservation therapy for patients and physicians.
About 40 percent of breast cancer patients who are eligible for a lumpectomy still choose total mastectomy over breast conservation therapy, despite published data demonstrating that the survival benefits are the same. Many of these patients decline breast conserving lumpectomy because they are unable to endure the time and travel burdens imposed by six to seven weeks of traditional external beam radiation therapy. MammoSite internally delivers targeted doses of radiation via a balloon catheter directly to the tumor site over the course of five days, minimizing radiation exposure to healthy tissue. The U.S. Food and Drug Administration (FDA) cleared the MammoSite for use in May 2002. SleepApneaInfo.com
SleepApneaInfo.com is the world’s first educational web site devoted solely to obstructive sleep apnea (OSA) and serves as the educational landscape for an issue-awareness campaign, entitled, “Sleep Well, Be Healthy,” that was commissioned in May 2004. The non-branded awareness campaign is committed to educating the public about obstructive sleep apnea (OSA), its symptoms and effects, and helping to improve the lives of the 18 million Americans afflicted with the condition. By serving as an objective, comprehensive resource for OSA sufferers, their family and friends, SleepApneaInfo.com strives to raise awareness of the health risks of obstructive sleep apnea and make progress toward increasing diagnosis and treatment rates. For more information, visit www.SleepApneaInfo.com.
|
